NDAINJECTIONINJECTABLE
Approved
May 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
ORAVERSE (phentolamine mesylate) by Septodont is soft-tissue anesthesia and the associated functional deficits is not fully understood. Approved for cardiovascular system disease. First approved in 2008.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ORAVERSE (phentolamine mesylate) is an injectable alpha-adrenergic antagonist that reverses soft-tissue anesthesia by producing vasodilation and increasing local blood flow. It is used to counteract the lingering numbness and functional deficits associated with local anesthetic injections containing epinephrine, particularly in dental settings.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30%), suggesting transition planning and potential team restructuring ahead.
Mechanism of Action
soft-tissue anesthesia and the associated functional deficits is not fully understood. Phentolamine mesylate, the active ingredient in OraVerse, produces an alpha-adrenergic block of relatively short duration resulting in vasodilatation when applied to vascular smooth muscle. In an animal model,…
Indications (1)
Career Relevance
ORAVERSE has no currently linked job openings and faces an approaching loss of exclusivity, indicating limited hiring and potential career headwinds for commercial roles. Positions on this product are best suited for early-career professionals seeking experience in niche specialty or late-stage lifecycle management rather than growth opportunities.
Worked on ORAVERSE at Septodont? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.